Prot# 109493 / MAGRIT: A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lun

  • DeCamp Jr, Malcom McAvoy (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/14/08 → 10/14/11

Funding

  • GlaxoSmithKline plc (109493 / MAGRIT)